Patents by Inventor Jan Tavernier
Jan Tavernier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9932409Abstract: The present disclosure relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The disclosure relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.Type: GrantFiled: July 4, 2014Date of Patent: April 3, 2018Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉMONTPELLIER 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIERInventors: Jan Tavernier, Sarah Gerlo, Frank Peelman, Gilles Uze
-
Patent number: 9914759Abstract: The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.Type: GrantFiled: July 18, 2014Date of Patent: March 13, 2018Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIERInventors: Jan Tavernier, Jennyfer Bultinck, Frank Peelman, Gilles Uze
-
Publication number: 20180057555Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.Type: ApplicationFiled: July 6, 2017Publication date: March 1, 2018Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
-
Publication number: 20180045719Abstract: This disclosure relates to a virus-like particle in which a small molecule-protein complex is entrapped, ensuring the formation of the small molecule-protein complex under physiological conditions, while protecting the small molecule-protein complex during purification and identification. The disclosure further relates to the use of such virus-like particle for the isolation and identification of small molecule-protein complexes.Type: ApplicationFiled: March 23, 2016Publication date: February 15, 2018Inventors: Jan Tavernier, Sven Eyckerman
-
Publication number: 20180028616Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.Type: ApplicationFiled: September 27, 2017Publication date: February 1, 2018Inventors: Jan Tavernier, Gilles Uzé, Guillaume Cartron, Franciane Paul, Jacob Piehler
-
Patent number: 9878014Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.Type: GrantFiled: September 28, 2016Date of Patent: January 30, 2018Assignees: VIB VZW, UNIVERSITEIT GENT, UNIVERSITÉ MONTPELLIER 2, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIERInventors: Jan Tavernier, Gilles Uzé, Guillaume Cartron, Franciane Paul, Jacob Piehler
-
Patent number: 9732135Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.Type: GrantFiled: July 1, 2014Date of Patent: August 15, 2017Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIERInventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
-
Publication number: 20170072020Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.Type: ApplicationFiled: September 28, 2016Publication date: March 16, 2017Inventors: Jan Tavernier, Gilles Uzé, Guillaume Cartron, Franciane Paul, Jacob Piehler
-
Patent number: 9492562Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.Type: GrantFiled: January 17, 2013Date of Patent: November 15, 2016Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE MONTPELLIER 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER, UNIVERSITAT OSNABRUCKInventors: Jan Tavernier, Gilles Uzé, Guillaume Cartron, Franciane Paul, Jacob Piehler
-
Publication number: 20160159874Abstract: The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.Type: ApplicationFiled: July 18, 2014Publication date: June 9, 2016Inventors: Jan Tavernier, Jennyfer Bultinck, Frank Peelman, Gilles Uze
-
Publication number: 20160152730Abstract: The present disclosure relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The disclosure relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.Type: ApplicationFiled: July 4, 2014Publication date: June 2, 2016Inventors: Jan Tavernier, Sarah Gerlo, Frank Peelman, Gilles Uze
-
Publication number: 20150153355Abstract: The disclosure relates to a virus-like particle in which a protein complex is entrapped, ensuring the formation of the protein complex under physiological conditions, while protecting the protein complex during purification and identification. The disclosure further relates to the use of such virus-like particle for the isolation and identification of protein complexes.Type: ApplicationFiled: May 24, 2013Publication date: June 4, 2015Inventors: Jan Tavernier, Sven Eyckerman
-
Publication number: 20150011417Abstract: The disclosure relates to a recombinant membrane span protein complex, comprising (1) a fusion protein, comprising a membrane span protein fused to a kinase domain, preferably a constitutive kinase and (2) a reporter construct comprising a polypeptide, interacting with the membrane span protein, fused to a reporter phosphorylation domain. The disclosure relates further to the uses of such membrane span protein complex for the detection of compounds that interact with the membrane span protein and for the screening and/or detection of inhibitors of the compound-membrane span protein interactions. In a preferred embodiment, the membrane span protein is a G protein coupled receptor (GPCR) and the method is used for the screening and/or detection of inhibitors of the ligand-receptor binding.Type: ApplicationFiled: March 6, 2013Publication date: January 8, 2015Inventors: Jan Tavernier, Samuel Lievens
-
Publication number: 20140348789Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.Type: ApplicationFiled: January 17, 2013Publication date: November 27, 2014Inventors: Jan Tavernier, Gilles Uzé, Guillaume Cartron, Franciane Paul, Jacob Piehler
-
Publication number: 20140030746Abstract: The disclosure relates to a cytoplasmic protein complex comprising: (a) a first recombinant fusion protein comprising a kinase, fused to a first interaction polypeptide; and (b) a second recombinant fusion protein comprising a domain comprising a reporter phosphorylation site, whereby the domain is fused to a second interaction polypeptide. The disclosure relates further to a method to detect compound-compound-interaction using the cytoplasmic protein complex, and to cells comprising such cytoplasmic protein complex.Type: ApplicationFiled: February 29, 2012Publication date: January 30, 2014Applicants: UNIVERSITEIT GENT, VIB VZWInventors: Jan Tavernier, Samuel Lievens
-
Patent number: 8048986Abstract: The invention relates to a recombinant receptor, comprising a ligand-binding domain and a signaling domain that comprises a heterologous bait polypeptide, which receptor is inactivated by binding of a prey polypeptide to the heterologous bait peptide, either in presence or absence of a ligand binding to the ligand-binding domain. The receptor is activated by addition of a compound that disrupts the bait-prey interaction. The invention also relates to a method of screening compounds that disrupt compound-compound binding using the recombinant receptor.Type: GrantFiled: December 14, 2009Date of Patent: November 1, 2011Assignee: Vlaams Interuniversitair Instituut Voor Biotechnologie VZWInventors: Sven Eyckerman, Jan Tavernier, Joel S. Vandekerckhove
-
Patent number: 8003757Abstract: Described is a recombinant receptor comprising an extracellular ligand-binding domain and a cytoplasmic domain that comprises a heterologous bait polypeptide. The recombinant receptor is activated by binding of a ligand to the ligand-binding domain and by binding of a prey polypeptide to the heterologous bait peptide. The invention also discloses a method for detecting compound-compound binding using the recombinant receptor.Type: GrantFiled: December 14, 2009Date of Patent: August 23, 2011Assignee: Vlaams Interuniversitair Instituut Voor Biotechnologie VZWInventors: Sven Eyckerman, Xaveer van Ostade, Joel S. Vandekerckhove, Annick Verhee, Jan Tavernier
-
Patent number: 7855270Abstract: The present invention discloses a recombinant receptor comprising an extracellular ligand-binding domain and a cytoplasmic domain that comprises a heterologous bait polypeptide. The recombinant receptor is activated by binding of a ligand to the ligand binding domain and by binding of a prey polypeptide to the heterologous bait peptide. The present invention also discloses a method for detecting compound-compound binding using the recombinant receptor.Type: GrantFiled: November 22, 2002Date of Patent: December 21, 2010Assignee: Vlaams Interuniversitair Instituut Voor Biotechnologie VZWInventors: Sven Eyckerman, Xaveer van Ostade, Joel S. Vandekerckhove, Annick Verhee, Jan Tavernier
-
Publication number: 20100173408Abstract: Described is a recombinant receptor comprising an extracellular ligand-binding domain and a cytoplasmic domain that comprises a heterologous bait polypeptide. The recombinant receptor is activated by binding of a ligand to the ligand-binding domain and by binding of a prey polypeptide to the heterologous bait peptide. The invention also discloses a method for detecting compound-compound binding using the recombinant receptor.Type: ApplicationFiled: December 14, 2009Publication date: July 8, 2010Inventors: Sven Eyckerman, Xaveer van Ostade, Joel S. Vandekerckhove, Annick Verhee, Jan Tavernier
-
Publication number: 20100174049Abstract: The invention relates to a recombinant receptor, comprising a ligand-binding domain and a signaling domain that comprises a heterologous bait polypeptide, which receptor is inactivated by binding of a prey polypeptide to the heterologous bait peptide, either in presence or absence of a ligand binding to the ligand-binding domain. The receptor is activated by addition of a compound that disrupts the bait-prey interaction. The invention also relates to a method of screening compounds that disrupt compound-compound binding using the recombinant receptor.Type: ApplicationFiled: December 14, 2009Publication date: July 8, 2010Applicant: Vlaams Interuniversitair Instituut Voor Biotechnologie VZWInventors: Sven Eyckerman, Jan Tavernier, Joël Vandkerckhove